In:
Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 31, No. 4_suppl ( 2013-02-01), p. 285-285
Abstract:
285 Background: Margin-negative (R0) surgical resection is the only potentially curative therapy for pancreatic cancer. For patients deemed borderline resectable (BL), neoadjuvant chemoradiotherapy (NCRT) increases the likelihood of subsequent R0 resection and improves overall survival. Prognostic factors for achieving resection following NCRT have yet to be clearly identified. Methods: 50 consecutive patients diagnosed with BL pancreatic cancer by a multidisciplinary tumor board from 2008-12 were retrospectively identified. Pre- and post-NCRT CT scans and surgical specimens were centrally reviewed by a blinded radiologist and pathologist, respectively. Results: 29 patients underwent resection following NCRT, while 21 remained unresectable. Between the two groups, age, gender, mean RT dose, and proportion of pancreatic head tumors were not significantly different. Lack of the following factors was favorably associated with resection: SMV/PV encasement (p=0.01), SMA involvement (p=0.02), ascites (p=0.01), and questionable/overt metastases (p=0.01). Notably, celiac artery involvement/encasement, common hepatic artery encasement, and percentage change in tumor volume were not significant predictors of resectability (all p 〉 0.05). Additionally, tumor volume and degree of individual vessel involvement did not significantly change from scans before and after NCRT (all p 〉 0.05). Median OS was 22.9 vs.13.0 months in resected and unresected patients, respectively (p 〈 0.001). Of resected patients, 93% had negative margins, 28% had positive nodes, 27% demonstrated 〈 10% viable tumor, and 12% had pathologic complete response at surgery. Conclusions: Certain radiographic features appear more strongly associated with resectability after NCRT than others. Despite the fact that tumor-vessel interactions do not change significantly due to NCRT, subsequent R0 resection rates are high, nodal involvement is low, nearly 1/3 of patients have minimal residual tumor, and outcomes are improved. Further studies are needed to elucidate novel biomarkers or functional imaging predictors for successful resection following neoadjuvant therapy.
Type of Medium:
Online Resource
ISSN:
0732-183X
,
1527-7755
DOI:
10.1200/jco.2013.31.4_suppl.285
Language:
English
Publisher:
American Society of Clinical Oncology (ASCO)
Publication Date:
2013
detail.hit.zdb_id:
2005181-5
Permalink